< Back to Press Releases
Wolfe Laboratories Hosts 2009 Biopharma Conference and United Way Fundraiser
BOSTON, MA – (BUSINESS WIRE) – February 19, 2009 – In celebration of their 10th Anniversary providing pharmaceutical ADMET and CMC development services to emerging pharma and biotech companies, Wolfe Laboratories, Inc. (WLI) is partnering with United Way to host the 2009 Wolfe Biopharma Conference to be held on April 2nd, 2009 at the Mandarin Oriental Hotel in Boston. This conference and fundraiser will help raise money for United Way’s Math, Science and Technology initiative(MSTi). All registration fees will directly benefit MSTi and other youth programs.
Filling Biopharma’s Pipeline will feature senior-level executives in biopharma, academia, venture capital, and media who will discuss the existing trends and challenges in the biopharma ecosystem. Experts will explore and address the current state and future of the biopharma industry to provide attendees with a better understanding about combining critical path activities in DMPK, form and formulation, and Phase I clinical supply, which results in significant time savings, thus increasing the rate at which the pipeline can be filled with high quality drug candidates. Moreover, speakers will address a wide range of topics including: a perspective from chemist-turned investor; the unique challenges of early biologics; how to position early stage assets for acquisition; and a case study on how to run a successful virtual company. With the variety and depth of topics, attendees are guaranteed to leave this conference with a plethora of knowledge.
Janet Wolfe, Ph.D., President of WLI and Greater Boston Chamber of Commerce’s 2008 Entrepreneur of the Year will kick off the evening with a brief introduction. The keynote address will be made by Ronald Borchardt, Ph.D., the Solon E. Summerfield Distinguished Professor of Pharmaceutical Chemistry, University of Kansas, who will discuss “Optimizing the ‘Drug-Like Properties’ of Leads in Drug Discovery.” Other expert speakers include Kazumi Shiosaki, Ph.D., Managing Director, MPM Capital; Patricia Hurter, Ph.D., Vice President, Pharmaceutical Development, Vertex Pharmaceuticals; Dhiren Thakker, Ph.D., Associate Dean for Research and Graduate Education, Ferguson Distinguished Professor of Molecular Pharmaceutics, University of North Carolina; Arthur Pappas, M.B.A., Managing Partner,Pappas Ventures; James White, Ph.D., CEO, CoLucid Pharmaceuticals; and Michael Powell, Ph.D., General Partner, Sofinnova Ventures.
Following the speaker presentations, there will be a plenary address made by Mark Fishman, M.D., President, Novartis Institutes for BioMedical Research; Steven Ainsley, Publisher, The Boston Globe; and Charles Kravetz, President, New England Cable News. They will discuss biotech ecosystems, life sciences in the media, and the importance of investing in youth. A cocktail reception and dinner delights will ensue.
To learn more about the specifics of this event, including speakers and session topics, visit http://www.wolfelabs.com/ or email firstname.lastname@example.org. To register, visit www.supportunitedway.org/wolfebiopharm.
About Wolfe Laboratories, Inc. (WLI)
Founded in 1999, WLI is a pharmaceutical development company located in Watertown, MA that offers a variety of customized pre-clinical services, including pre-formulation and formulation development, analytical method development and characterization, PK and in vitro ADME bioanalytical development, dose formulation stability and uniformity assessment, lyophilization cycle development, IND enabling and GLP/GMP analytical testing and method validation services. For more information, visit www.wolfelabs.com.